Recent Business Highlights
- Total prescriptions continued to grow for JATENZO in the fourth quarter of 2021 with an increase of 11% sequentially and 81% year-over-year driven primarily by advertising and promotion and an increase in payer coverage across all payer channels
- Two new patents for JATENZO issued in November 2021
- Closed a $15 million private placement with a leading healthcare investor in December 2021, the proceeds of which support the ongoing commercialization of JATENZO
- Appointed Dr. Zhanna Jumadilova as Chief Clinical Development Officer in January 2022
- Launched strategic partnerships with Vault Health and AssistRx to enhance the patient experience in February 2022
- Initiated screening for the first patient in an investigator-initiated Phase 4 clinical trial of JATENZO for the treatment of hypogonadal men with chronic kidney disease (CKD) in March 2022; expect to announce results from the trial in the first half of 2023
- Recently initiated process to explore strategic alternatives to maximize stockholder value
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.